**Author details**

Chandra Prajapati1 and Katriina Aalto-Setälä1,2\*

1 Faculty of Medicine and Life Technology, BioMediTech, University of Tampere, Tampere, Finland

2 Heart Hospital, Tampere University Hospital, Tampere, Finland

\*Address all correspondence to: katriina.aalto-setala@uta.fi

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**75**

*Modelling of Genetic Cardiac Diseases*

**References**

*DOI: http://dx.doi.org/10.5772/intechopen.84965*

and variable expressivity in heritable cardiac arrhythmia syndromes. Translational Research. 2013;**161**:1-14

[8] Shinozawa T, Nakamura K, Shoji M, Morita M, Kimura M, Furukawa H, et al. Recapitulation of clinical individual susceptibility to drug-induced QT prolongation in healthy subjects using iPSC-derived cardiomyocytes. Stem Cell

Reports. 2017;**8**(2):226-234

com/2079-7737/7/1/3

pubmed/20031583

[9] Coll M, Pérez-Serra A, Mates J, del Olmo B, Puigmulé M, Fernandez-Falgueras A, et al. Incomplete

penetrance and variable expressivity: Hallmarks in channelopathies associated with sudden cardiac death. Biology (Basel) [Internet]. 2017;**7**(1):3. Available from: http://www.mdpi.

[10] Kelly M, Semsarian C, Cirino AL, Ho CY, Ashley EA. Multiple mutations in genetic cardiovascular disease: A marker of disease severity? Circulation: Cardiovascular Genetics [Internet]. 2009;**2**(2):182-190. Available from: http://www.ncbi.nlm.nih.gov/

[11] Veltmann C, Barajas-Martinez H, Wolpert C, Borggrefe M, Schimpf R, Pfeiffer R, et al. Further insights in the most common SCN5A mutation causing overlapping phenotype of long QT syndrome, Brugada syndrome, and conduction defect. Journal of the American Heart Association. 2016;**5**(7)

[12] Spoladore R, Maron MS, D'Amato

Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence. European Heart

[13] McAnulty J, Halperin B, Kron J, Larsen G, Raitt M, Swenson R, et al. A comparison of antiarrhythmicdrug therapy with implantable

R, Camici PG, Olivotto I.

Journal. 2012;**33**:1724-1733

[1] Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. Journal of the American College of Cardiology. 2017;**70**(1):1-25

[2] Meyer L, Stubbs B, Fahrenbruch C, Maeda C, Harmon K, Eisenberg M, et al. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: A 30-year review. Circulation.

2012;**126**(11):1363-1372

2013;**45**(1):85-90

[3] Jääskelainen P, Helio T, Aalto-Setala K, Kaartinen M, Ilveskoski E, Hamalainen L, et al. Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population. Annals of Medicine.

[4] Christiaans I, Nannenberg EA, Dooijes D, Jongbloed RJE, Michels M, Postema PG, et al. Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Netherlands heart journal: Monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2010;**18**(5):248-254

[5] Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, et al. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation. 2005;**112**(17):2602-2610

[6] Giudicessi JR, Ackerman MJ. Genotype- and phenotype-guided management of congenital long QT syndrome. Current Problems in Cardiology. 2013;**38**(10):417-455

[7] Giudicessi JR, Ackerman MJ.

Determinants of incomplete penetrance

*Modelling of Genetic Cardiac Diseases DOI: http://dx.doi.org/10.5772/intechopen.84965*
